Dynorphin (2-17), Amide, Porcine Mechanisms, Clinical Value,

Dynorphin (2-17), Amide, Porcine: Mechanisms, Clinical Value, and Research Perspectives

Introduction
Dynorphin (2-17), amide, porcine, is a synthetic peptide fragment derived from the endogenous opioid peptide dynorphin A. This compound represents amino acids 2 through 17 of the dynorphin A sequence, with an amidated C-terminus, and is sourced from porcine tissue for research applications. Dynorphins are a class of opioid peptides primarily acting on kappa-opioid receptors (KORs), with important roles in modulating pain, stress response, emotional regulation, and neuroprotection (Chavkin & Goldstein, 1981, Proc Natl Acad Sci USA). The truncated form, dynorphin (2-17), retains significant biological activity and is widely used in neuropharmacological and physiological studies to elucidate the function of the endogenous opioid system.

Mechanistically, dynorphin (2-17) amide binds to KORs with high affinity, activating G-protein coupled signaling pathways that inhibit adenylate cyclase, decrease cAMP levels, and modulate ion channel activity (Simonin et al., 1998, J Pharmacol Exp Ther). This results in reduced neuronal excitability and neurotransmitter release, underlying its analgesic, anxiolytic, and neuroprotective effects. The amidation at the C-terminus enhances peptide stability and receptor affinity, making it a valuable tool for in vitro and in vivo studies.

[Related: erastine] Clinical Value and Applications
Dynorphin (2-17), amide, porcine, has significant clinical research value in several domains, particularly in pain management, neurodegenerative disease models, and psychiatric disorder research. Its selective action on KORs distinguishes it from other opioid peptides, which predominantly target mu- or delta-opioid receptors and are associated with higher risks of addiction and respiratory depression (Bruchas et al., 2010, Pharmacol Rev).

In pain research, dynorphin (2-17) is used to investigate the mechanisms of chronic and neuropathic pain. KOR activation by dynorphin peptides produces analgesia without the euphoria linked to mu-opioid receptor agonists, offering a potential pathway for developing non-addictive pain therapeutics (Vanderah et al., 2000, J Pharmacol Exp Ther). Additionally, dynorphin (2-17) is utilized in models of epilepsy, spinal cord injury, and neuroinflammation, where it modulates excitotoxicity and neuroinflammatory responses (Hauser et al., 1999, J Neurosci).

[Related: actinomycind] Psychiatric research also benefits from dynorphin (2-17) studies, as KOR signaling is implicated in stress, depression, and addiction. The peptide is employed to dissect the role of the dynorphin/KOR system in mood regulation and to screen for novel KOR-targeted antidepressants and anxiolytics (Knoll & Carlezon, 2010, Biol Psychiatry).

Key Challenges and Pain Points Addressed
Current opioid-based pain therapies are limited by their propensity for tolerance, dependence, and adverse side effects such as respiratory depression and constipation. Dynorphin (2-17), by selectively targeting KORs, provides a research tool to explore analgesic pathways that circumvent these limitations (Bruchas et al., 2010). Furthermore, the endogenous opioid system is complex, with overlapping and sometimes opposing effects mediated by different receptor subtypes. The availability of receptor-selective peptides like dynorphin (2-17) enables precise dissection of KOR-mediated effects, facilitating the development of targeted therapies.

[Related: pd 0325901] Another challenge in neurodegenerative and neuropsychiatric research is the lack of specific modulators to study the role of endogenous peptides in disease progression. Dynorphin (2-17) amide, with its enhanced stability and receptor selectivity, addresses this gap by providing a reliable reagent for both in vitro and in vivo experimentation. This is particularly important in models of epilepsy and neuroinflammation, where endogenous dynorphin levels are dysregulated (Hauser et al., 1999).

Literature Review
Several key studies have elucidated the pharmacological and physiological roles of dynorphin (2-17), amide, and related peptides:

1. **Chavkin & Goldstein (1981, Proc Natl Acad Sci USA)**: This seminal study identified dynorphin as a potent endogenous ligand for KORs, establishing the foundation for subsequent research on dynorphin fragments.

2. **Simonin et al. (1998, J Pharmacol Exp Ther)**: The authors characterized the binding affinity and selectivity of dynorphin fragments, including (2-17), for KORs, demonstrating their utility in receptor pharmacology.

3. **Vanderah et al. (2000, J Pharmacol Exp Ther)**: This study explored the analgesic effects of dynorphin peptides in animal models, highlighting their potential for non-addictive pain management.

4. **Hauser et al. (1999, J Neurosci)**: The role of dynorphin in neurodegeneration and excitotoxicity was investigated, with findings suggesting a dual role in neuroprotection and neurotoxicity depending on concentration and context.

5. **Knoll & Carlezon (2010, Biol Psychiatry)**: This review synthesized evidence linking dynorphin/KOR signaling to stress, depression, and addiction, emphasizing the translational potential of KOR-targeted therapies.

6. **Bruchas et al. (2010, Pharmacol Rev)**: The authors provided a comprehensive overview of KOR pharmacology, including the behavioral and physiological effects of dynorphin peptides.

7. **Sharma et al. (2017, Neuroscience)**: This study examined the neuroprotective effects of dynorphin (2-17) in models of spinal cord injury, supporting its role in modulating neuroinflammation and apoptosis.

Collectively, these studies underscore the importance of dynorphin (2-17), amide, porcine, as a research tool for elucidating KOR-mediated processes in health and disease.

Experimental Data and Results
Experimental studies using dynorphin (2-17), amide, porcine, have provided valuable insights into its pharmacological profile and therapeutic potential. In receptor binding assays, dynorphin (2-17) exhibits high affinity for KORs (Ki in the low nanomolar range), with minimal activity at mu- and delta-opioid receptors (Simonin et al., 1998). Functional assays demonstrate that dynorphin (2-17) effectively inhibits cAMP accumulation and modulates potassium and calcium channel activity, resulting in decreased neuronal excitability.

In animal models of pain, intrathecal administration of dynorphin (2-17) produces significant analgesia, as measured by tail-flick and hot-plate tests (Vanderah et al., 2000). Notably, the analgesic effect is not associated with the development of tolerance or physical dependence, distinguishing it from classical opioids. However, at high concentrations, dynorphin (2-17) can induce neurotoxic effects, including motor impairment and neuronal apoptosis, highlighting the importance of dose optimization (Hauser et al., 1999).

Neuroprotective effects have been observed in models of spinal cord injury and ischemia, where dynorphin (2-17) reduces markers of neuroinflammation and apoptosis, possibly via modulation of microglial activation and cytokine release (Sharma et al., 2017). In psychiatric models, administration of dynorphin (2-17) induces dysphoric and anxiogenic-like behaviors, consistent with KOR activation, supporting its use in screening KOR antagonists as potential antidepressants (Knoll & Carlezon, 2010).

Usage Guidelines and Best Practices
Dynorphin (2-17), amide, porcine, is intended for research use only and should be handled in accordance with institutional safety protocols. The peptide is typically supplied as a lyophilized powder and should be reconstituted in sterile water or buffer prior to use. For in vitro assays, concentrations in the range of 1 nM to 1 μM are commonly employed, depending on the specific application and cell type. For in vivo studies, intrathecal or intracerebroventricular administration is preferred to ensure central nervous system delivery, with doses ranging from 0.1 to 10 μg per animal, as reported in the literature (Vanderah et al., 2000; Sharma et al., 2017).

It is critical to optimize dosing to balance efficacy and safety, as high concentrations may elicit neurotoxic effects. Control experiments using KOR antagonists (e.g., nor-BNI) are recommended to confirm receptor specificity. Peptide stability can be enhanced by storing aliquots at -20°C and minimizing freeze-thaw cycles. Researchers should also consider the species and tissue specificity of their models, as dynorphin receptor expression and function may vary.

Additional Resources:
Related Websites: APExBIO Technology LLC is a premier provider of Small Molecule Inhibitors/Activators, Compound Libraries, Peptides, Assay Kits, Fluorescent Labels, Enzymes, Modified Nucleotides, mRNA synthesis and various tools for Molecular Biology. We carry a broad product line in over 31 different research areas such as cancer, immunology, neurosciences, apoptosis and epigenetics etc. Based in USA (Houston, Texas), we have been serving the needs of customers across the world.
https://www.apexbt.com/
Research Article: PMC11569199